{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T16:20:55Z","timestamp":1698423655260},"reference-count":20,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,2,28]],"date-time":"2007-02-28T00:00:00Z","timestamp":1172620800000},"content-version":"vor","delay-in-days":4307,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Statistics in Medicine"],"published-print":{"date-parts":[[1995,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To infer patterns of average systemic exposure and to estimate individual exposures in phase III clinical trials of a new anxiolytic, two statistical methodologies were applied and compared: non\u2010linear mixed\u2010effect modelling, and a model\u2010free approach based on quartiles of dose\u2010normalized plasma concentrations of the drug. Although the model\u2010based approach provides more quantitative insight about relationships between average exposure and demographic covariates, the model\u2010free approach provides qualitatively similar results about average clearance and quantitatively similar results about individual exposures, and the model\u2010free approach is easy and inexpensive to implement.<\/jats:p>","DOI":"10.1002\/sim.4780140915","type":"journal-article","created":{"date-parts":[[2007,4,29]],"date-time":"2007-04-29T19:16:37Z","timestamp":1177874197000},"page":"955-968","source":"Crossref","is-referenced-by-count":1,"title":["INFERRING SYSTEMIC EXPOSURE FROM A PHARMACOKINETIC SCREEN: MODEL\u2010FREE AND MODEL\u2010BASED APPROACHES"],"prefix":"10.1002","volume":"14","author":[{"given":"Jerry R.","family":"Nedelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel H.","family":"Karara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Tao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Gibiansky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William T.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,2,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.47"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.222"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03230.x"},{"key":"e_1_2_1_5_2","volume-title":"NONMEM Users Guides, Version IV","author":"Beal S. A.","year":"1992"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2307\/2532087"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.2307\/2532734"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061470"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0096-3003(91)90077-Z"},{"key":"e_1_2_1_10_2","volume-title":"New Strategies in Drug Development and Clinical Evaluation: The population Approach","author":"Mentre F.","year":"1992"},{"key":"e_1_2_1_11_2","volume-title":"Statistical Methodology in the Pharmaceutical Sciences","author":"Racine\u2010Poon A.","year":"1990"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01064424"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061469"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.102"},{"key":"e_1_2_1_15_2","volume-title":"New Strategies in Drug Development and Clinical Evaluation: The Population Approach","author":"Ebelin M.\u2010E.","year":"1992"},{"key":"e_1_2_1_16_2","volume-title":"Exploratory Data Analysis","author":"Tukey J. W.","year":"1977"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602538409015066"},{"key":"e_1_2_1_18_2","unstructured":"Karara A. H.andFilipek R.\u2018Validation of an HPLC method for the analysis of the novel anxiolytic abecarnil in plasma\u2019 abstract of a paper presented at the American Association of Pharmaceutical Scientists National Meeting Washington D. C. November1991."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062831"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600710332"}],"container-title":["Statistics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fsim.4780140915","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/sim.4780140915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T04:07:45Z","timestamp":1698293265000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/sim.4780140915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,5,15]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1995,5,15]]}},"alternative-id":["10.1002\/sim.4780140915"],"URL":"https:\/\/doi.org\/10.1002\/sim.4780140915","archive":["Portico"],"relation":{},"ISSN":["0277-6715","1097-0258"],"issn-type":[{"value":"0277-6715","type":"print"},{"value":"1097-0258","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,5,15]]}}}